Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis.
K. E. Bickel
No relevant relationships to disclose
J. C. Niland
No relevant relationships to disclose
R. Mamet
No relevant relationships to disclose
C. C. Zornosa
No relevant relationships to disclose
D. S. Ettinger
Employment or Leadership Position - NCCN; NCCN
K. Pisters
No relevant relationships to disclose
G. A. Otterson
Consultant or Advisory Role - Celgene; Genentech
Research Funding - Celgene; Genentech; Pfizer; Taj Pharmaceuticals
M. Koczywas
Consultant or Advisory Role - Genentech
Honoraria - Genentech; Lilly
Research Funding - GlycaNova
M. E. Reid
No relevant relationships to disclose
M. S. Rabin
No relevant relationships to disclose
T. A. D'Amico
Employment or Leadership Position - NCCN
C. Earle
No relevant relationships to disclose
T. M. Pini
No relevant relationships to disclose
G. P. Kalemkerian
Research Funding - Lilly; Pfizer